MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
NCT01501487
Completed
Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients. This study is designed to test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and TheraPrint®, as well as traditional pathologic and clinical prognostic factors, to predict responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer (LABC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/26/2018
Locations: University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama +8 locations
Conditions: Breast Cancer
Register for Updates
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
NCT01234038
Completed
The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2018
Locations: Achieve Clinical Research, Birmingham, Alabama +28 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
NCT02122770
Completed
The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose administration of itraconazole on the single-dose IV PK of MLN4924.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2018
Locations: Winship Cancer Institute at Emory University, Atlanta, Georgia +3 locations
Conditions: Advanced Solid Tumors
Register for Updates
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
NCT00527735
Completed
The purpose of the study is to determine whether ipilimumab given with paclitaxel/carboplatin has clinical benefit when compared with paclitaxel/carboplatin alone in patients with previously untreated lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2018
Locations: Birmingham Hematology & Oncology Assoc. Llc, Birmingham, Alabama +71 locations
Conditions: Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
NCT01006252
Terminated
The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2018
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +121 locations
Conditions: Melanoma
Register for Updates
Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants
NCT00228319
Completed
The purpose of this study is to try and understand if there is added benefit or increased harm when antioxidant nutritional supplements are added to traditional chemotherapy in the treatment of ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/16/2018
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Ovarian Cancer
Register for Updates
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
NCT00088829
Terminated
RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment. PURPOSE: This clinical trial is studying how well genetic testing works in predicting response to paclitaxel in women who have unresected breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/15/2018
Locations: Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia
Conditions: Breast Cancer
Register for Updates
High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
NCT01921751
Terminated
This randomized phase II trial studies how well high or standard intensity radiochemotherapy after gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) work compared with gemcitabine hydrochloride and nab-paclitaxel alone in treating patients with pancreatic cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2018
Locations: Kaiser Permanente Oakland-Broadway, Oakland, California +45 locations
Conditions: Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer
Register for Updates
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
NCT02195973
Completed
The purpose of this study is to find out if a new drug, LDE225, is safe and has beneficial effects when combined with paclitaxel in women with platinum resistant ovarian cancer. Platinum resistant ovarian cancer refers to recurrent ovarian cancer that has undergone chemotherapy inclusive of a platinum compound (e.g. carboplatin or cisplatin).
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
06/14/2018
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Recurrent Ovarian Cancer
Register for Updates
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
NCT00268450
Terminated
RATIONALE: Drugs used in chemotherapy, such as cisplatin, gemcitabine, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blo... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/13/2018
Locations: Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina +3 locations
Conditions: Bladder Cancer
Register for Updates
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
NCT02060253
Completed
This phase I trial studies the side effects and best dose of ganetespib when given with paclitaxel, trastuzumab and pertuzumab in treating patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2018
Locations: NYU Cancer Institute, New York, New York +1 locations
Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Register for Updates
AZD2014 and Weekly Paclitaxel in Squamous NSCLC
NCT02403895
Terminated
Open--label, phase 2a, multi-centre, single-arm study to assess the efficacy and safety of AZD2014 and weekly paclitaxel in patients with squamous non-small cell lung cancer (NSCLC)
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/04/2018
Locations: Research Site, Boston, Massachusetts +6 locations
Conditions: Squamous Non Small Cell Lung Cancer
Register for Updates